Member Info for Num4

They can't buy at the moment as they know the details of the study that haven't yet been published. Once the peer article is released they may be able to buy, but reading between the lines Stephen is playing hardball, with I hope Clive, who had a role upgrade to get the best terms for what is a blockbuster.

I don't think we'll see the end of the tox studies without a partner, look at the coverage you get from dual inhibition, we're producing better safety profiles than Pfizer at 100mg, the pasi-75 could be in the 90% regain. The revenue potential (what it comes down to at the end of the day) is huge. A steer from a partner company has told them, don't prove efficacy, we know it's a clinically validated target and you've got the biomarker evidence to prove it.

It's only been a few hours since all this new information from John on the study, obviously those under NDA will be aware and as expected following it very closely.

Stephen has just told anyone who has made or thinking about making an offer, stump up what you know it's worth and we are open to a deal. If not, we're confident to do phase 2.

You can be assured that Pfizer are looking very seriously at these direct comparisons between 1801 and brepocitinib. Johns basically laying it out from 12minutes in how much better from a safety profile 1801 looks to be compared directly with Pfizer.

Market share should be favourable to Sareum.

Once this is digested and then supported with the peer article we will see some real interest.

I really don't think we could have asked for more, forget the share price at the moment, this could have went another way with these results and I think we are taking it for granted what this dataset has produced.

This is gunna be huge and well worth the wait.

It's quite clear that the strategy has been adjusted, the application for 1b was submitted and accepted by our OZ friends, something has changed which Sareum now feel that a 4month tox study is of more value to a license deal than a 1b.

So they've either been advised to do this or directly asked by a licensor. Clive Birch has also had a title upgrade, perhaps the involvement is increasing at these interesting times.

Best in class is clearly the new line for 1801, with the biomarkers showing dose dependant reductions what is the point of going into psoriasis in 1b, everything in science tells them it's going to reduce psoriasis, perhaps this is the reason for the tox studies. Details of that is what is needed, is it being ran out of OZ, I hope so.

I guess it's all about making 1801 as attractive as possible at early stages, the parents have a number of autoimmune diseases in reference so along with psoriasis, can we expand the dataset to further disease. The thing about biomarkers is you can't monitor them all, so you need to know where to look to prove some form of inhibition or reduction. A phase 3 asset would go back and do a phase 1 in another disease.

I think we're basically saying, 1801 is going to be best in class for psoriasis but let us know show you what else it can do so you pay the money to license which we want and the shareholders expect.

Parker at the helm seems to have brought some third party confidence in the immediate future of Sareum. He has finally delivered on the II's, something he got stoned for previously.

It really does question why they had to do RF previously and what has changed from then to now. Anyway, it's the past, the immediate future looks secure and the upcoming "long term" tox study is a clear indication that whoever they're currently talking to has a few months to ink the deal on Sareums terms or they continue with phase 2 themselves.

Share price is grossly undervalued at present, a nice 50% rise is due after these last 2 RNS, a further II RNS to take it to 3 at a higher price if 50p per share would take this back to the £'s. Then the release of annual report and publish of data in peer journal keeps us there until we agree terms or we continue to phase 2. Either way, we are in a strong position to be at the negotiating table. Patents, yes, immediate funding, yes, Institutions, yes, Safety, yes. Potential market size 35/40billion £. We'll take a billion and some shares in licensor company.

Good luck all

The data will go to a peer reviewed journal.

Parker has just made good on his II, took time but they're now in.

The message to licensors is, up your offer or we'll go it alone with II and HNWI support.

Clearly a demand for this tox data from a licensor imo.

Parker just retweeted the Edison post which has a comment about when will he start earning his wage... Signal that it's now hopefully.

Either way the side step from Tim is going to be good news for us shareholders.

1. A deal is in the works and this was a condition - win

2. New CEO appointed and will obviously want to promote the pipeline and bring fresh enthusiasm to the business - win

Question I have is, if there is a deal then why not announce that at the same time, why wait.

Option 2 is more viable to me.

Congratulations everyone who has kept the faith. A very positive outcome from the Phase 1a trial of which I'm sure will be instantly shared with all potential investors and interested parties for further development. It's safe and can be administered once daily. As mentioned this also derisks SDC-1802.

Whatever value Sareum have placed on these compounds will be met and exceeded. From the depths of 10p we move forward with a best in class molecule which is ready to license.

I think we can say the timeline was met and strategic decision to release on a Monday moved it out of H1 timescales. Another positive that we now meet timescales set by the company.

This is going to be good. Enjoy

Hi SOG,

Now the wider investment market needs to recognise the opportunity - the next RNS for topline data is critical, Sareum need to go all out. I would prefer proceeds if the raise to go into PR for topline data than SDC1802 to be honest.

Give Elon some money Tim, or get Jeb Keiper on the board for a 12month fixed term advisory role. What a message that would send!

Evening all investors. I think we all knew the WRAP would be oversubscribed, and the calls for why we didn't do this before are warrented. I think this still goes back to the MHRA as to the main reason for the threats on the financials - I think the BoD had high confidence in that being approved, if you recall - we paid trial design "experts" for months and I'm sure John knows his way aorund the MHRA as he does with the patent board, for those that have seen the patent discussions from years back will remeber the level of competence John portrayed, in the end - winning the argument for compound differentiation (if my memory is correct).

The opportunity was (IMO) lined up, get the MHRA approval (Nailed On, so it seemed), then do the placing of shares in the multple of £'s. Everyone is a winner and the board would have been the best thing since sliced bread.

Albeit, that's not how it played out for unknown reasons, potentially one of the scenario's I've read below, I'm sure Sareum still don't know. But in the world of multi-billion pound deals nothing is off the table.

So the treat to finanacing continued as we seen it play out until today when I now believe we have enough to move forward with a level of confidence in the product and a shift to a Phase 2a approach. To enable the rich to get richer it's now at 10p - I don't expect it to be here for long - we are now in the opportunity phase again with the next threat being that of poor P1a top line data, hopefully the nailed on presumptions are correct this time around.

The levels of opportunity now exist on both sides, investors to make money and the BoD to rescue their credability and competence to run this into a high value license deal. I do believe Tim and John should take a pay cut until a license is agreed. I also believe Parker is on his last chance with shareholders and HNWI's. I think once a license is signed for SDC-1801 then Sareum should buyback a substantial amount of the shares until a takeover is completed. It's at that point when the takeover happens for 100+% premium on the SP, with the opportunities mentioned above and the reduced levels of threat then I think we can get back to a market cap of £300million+ pre-takeover. No failures or delays in SDC-1801 to date and I don't anticipate any, the only failure was the finance, as mentioned above.

I'm not convinced on using new capital for SDC-1802 at the moment though. Need more substance than the usual lines of translational studies, unless a clear pathway can be communicated with shareholders.

Good luck to all genuine investors.

Https://www.fiercebiotech.com/biotech/gilead-pays-435m-xilios-early-phase-il-12-prospect-entering-race-after-rivals-exit

This is what we're waiting for, all genuine investors and LTH are waiting for a license, obviously we could sell, and probably have sold on previous highs making a substantial amount of money. To say it's not investible is very short sighted.

Nobody cares about what happened with finances when they sign a license, they need the compound to be viable to do that and to date nothing suggests it's not a blockbuster.

Take a look at Jeb Keipers comments before Nimbus signed a $4 billion deal for their TYK2 compound.

We've moved to a P2a strategy, possibly OZ driven as original admission was with MHRA. Those who talked about doing the trial in UK - no chance. MHRA are the ones that set us on this path of financial woe in the first place.

A shift in strategy here. We're now going for a phase 2a after 1a.

All good on SDC-1801. The license if that compound is what every is waiting on and is the exit for all genuine LTH.

The only thing more annoying than the Sareum SP at the moment is trying to use LSE on a mobile.

Enjoy fellas!

Anyone heard from RMM?

At the end of the day, the value of Sareum is in the patents, they're assigned to Sareum as a public company, of which we have shares in.

Bio deals are the most creative deals I've seen in terms of future commitments, let's see where we are when the data is announced as to be honest this SP doesn't change my mind about my investment - I wouldn't have sold leading up to the data release anyway, and if it's bad which my belief is that it won't be then we would be at this level and lower in anyway.

Don't know why you would sell now if you've held for the data of P1a and P1b? We still haven't got that so why panic sell. This situation is no different that any other odd year where they needed to raise funding, before the HNWI it was like clockwork for the placings. I remember Parker commenting that they had supportive investors which lead is on the think finance wouldn't be an issue, hence the spike to the heights of £4+. Who knows what factors have came in to play since that, but it appears we had no contingency, or they were also flawed.

Andy, Paul, SAD etc al, feel free to email me on num4lse@gmail.com

I can't make tomorrow unfortunately.

Unbelievable share price, could have bought and sold this company over a few times with the volatility over the years. Nobody would have thought we would be in this position during our Phase 1a for a potential blockbuster with positive early indications to date.

Parker has really got his work cut out if he is to remain as chairman of Sareum. He needs to call in an old favour it seems. No doubt whatever happens with funding - we won't see the full picture. I'm ok with that, as we seen the full picture of what RV was and look what that has done to the SP.

Hence why Sareum keep everything close to their chest, so we may moan about why we don't get to see the data or who the investors are etc, but when we had full disclosure with RV the market also has full disclosure and decided to take Sareum to this position, as they can smell blood.

I do feel sorry for Tim and John as the stress they must be under at the moment will be relentless, I'm hoping no knee jerk reactions are made as they will come out of this downward trend with a compound that is worth multiples of this market cap.

Parker should have been the answer to their financing upto a license but he hasn't delivered on what he was brought in to achieve, can he now get us out of it is the question. Our NED's should have also seen this coming and advised accordingly.

Dissappointment alround and unfortunatly the buck stops with Tim as the CEO.

I have no doubt that a deal will be on the table for SDC-1801 after P1a, the temptation to take it might now be overwhelming.

Read Brightys post, parents expiring, billions is sales for Psoriasis and only growing.

SDC-1801 is a new compound with patent approved in Japan and pending in rest of world.

This is exactly what pharma's want, with once daily oral dosing.

Timescales won't be missed as it's not Sareum in control, the CRO are noted for improving timescales not delaying them, pharmasols.com is the CRO.

"therapeutically effective dose levels with no serious adverse events"

Enjoy the journey all.

Not claiming to be a WiP character as we all know how that ended. But I do speak to an individual, and I call them an individual as a VP is one pharma is different to a VP in another. If you know, you know.

The message is that there is huge motivation and pressure to shortening the time to market, how to shorten that timeframe and take compounds from phase 1 to phase 3.

I think we all need to realise the money involved here as we move forward, Tim and John probably (hopefully) realise that. Hence the "noted" phrases they tend to use in recent tyk2 deals and approvals.

If we have good results from phase 1b, somebody tell me why we wouldn't go to a phase 3. As I have it on good information that this is what big pharma are moving towards. Patent expiration should never be overlooked, the ultimate driver for all of this is profit for the company buying the molecule. Competition can and do take a molecular structure from the patent information, add a sugar molecular and then go to market. Speed is everything and to Sareums due, they have been on time with everything since trials started.

Everyone is here to make money but the real money is not the brokers or the traders in London, it's the executives and board of the pharmas, are we on their radar.. with a trial for Psoriasis in competition with a supermajor BMS and now Takeda, don't underestimate the importance of this Phase 1b. Which we will have results for by the end of this year.

Yes, we have been hammered by multiple factors, but the potential is still there and has only got stronger.

Do you believe in the potential or not, we are close, hold the course, buy Sareum or keep buying lottery tickets. I only gamble when I know I'll win and I'm all in.

The fact that it has been disclosed that Takeda beat almost every other bio to this deal gives you an insight to how hot these inhibitors are turning out to be. As the saying goes, strike while the iron is hot - Sareum are finding themselves in the hot zone with a strike approaching, confirming their strategy of pre-clinical, early clinical deals.

I believe there is enough science out there to show that our molecule with the addition of Jak1 will prove greater efficacy in some disease models. There is not a one pill fits all here for the multitude of autoimmune and cancer disease's. BMS and or Nimbus, now Takeda, molecules will be better in some indications, but certainly not all, leaving a market share for a tyk2/Jak1. BMS and Takeda are now clearly head to head competition with their allosteric and Takeda think they are superior.

We on the other hand are letting the big boys fight it out with that and have a molecule which differentiates from them both.

In a few months we will have a molecule with proven P1a safety data to enter this space, I have no doubt that discussions are taking place with the very companies that entered the bidding for Nimbus molecule, whilst BMS and Takeda have huge departments who look at competition to their assets and projected business models, if a small company like Sareum can disrupt that projected cashflow then they must do something about it or answer to the board why they didn't.

It has been a very long journey here and we've lost some along the way, plenty lessons learnt from Sareum's perspective but at least they are wiser and look to have the right NED support to get this over the line with a positive outcome for them and the shareholders.

Chk1 deal, as mentioned - an extension of previous agreement really, nothing much to shout about yet. CPF haven't done it justice but that's what happens in this industry. Just look at the history of Momelotinib with the Sierra deal. I mean, this is just not imaginable really. Pay $3m cash upfront in 2018, sell it 4 years later for $1.9billion.

Hence the share options for Sareum are them getting a bit wiser and understanding that these things change from dead duck to golden goose in a "pharma short" amount of time.

https://www.evaluate.com/vantage/articles/news/deals-snippets/glaxo-sierras-momelotinib-finds-its-fifth-owner

I hope they continue with the discussions and negotiate share options as part of any SDC-1801 deal.

Interest, as always, will return. Good luck for 2024 to all.

Happy New year to all.

I wonder how many other CPF deals have included shares, or is this Tim and Co. Learning their lesson from what could have been at Sierra.

As others have said I wouldn't be surprised if Nick Glover was involved, he took Momo for 3million I think..

Good luck for the year all.